- Conditions
- HIV, HIV Infections
- Interventions
- DTG/3TC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1
- Interventions
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
- Conditions
- Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- FS118, Paclitaxel
- Drug
- Lead sponsor
- invoX Pharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 4 more
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Symptomatic Genetic Dilated Cardiomyopathy
- Interventions
- danicamtiv, Placebo
- Drug
- Lead sponsor
- Kardigan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- Advanced Solid Tumors
- Interventions
- EMB-02
- Biological
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Colorado Springs, Colorado • Greenville, South Carolina
- Conditions
- Bioequivalence Study in Healthy Subjects, PK/PD
- Interventions
- 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
- Conditions
- Healthy
- Interventions
- Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Healthy
- Interventions
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Asthma
- Interventions
- FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 49
- States / cities
- Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
- Conditions
- Metastatic Cancer, Solid Tumor
- Interventions
- Sym021, Sym022, Sym023, Irinotecan Hydrochloride
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more
- Conditions
- Melanoma
- Interventions
- Fianlimab, Cemiplimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
- Conditions
- Breast Carcinoma
- Interventions
- eftilagimod alpha, Paclitaxel, placebo
- Biological · Drug · Other
- Lead sponsor
- Immutep S.A.S.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more
- Conditions
- Hypercholesterolaemia
- Interventions
- Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 77
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 10,355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 269
- States / cities
- Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
- Conditions
- Healthy Volunteer Study
- Interventions
- Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
- Conditions
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- DTG, RPV, DTG/RPV FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HIV-1
- Interventions
- DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF/VEL/VOX, SOF/VEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more